New evidence suggests vitamin D may enhance short-term outcomes in oral lichen planus. Learn more about its role as an ...

Please provide your email address to receive an email when new articles are posted on . At week 28, 88% of patients treated with combination therapy achieved 75% disease severity reduction vs. 47% on ...

PITTSBURGH, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotechnology company dedicated to addressing serious diseases with significant unmet needs, ...

LP-310 shows significant improvements in pain and inflammation for oral lichen planus, with favorable safety results in Phase 2a trial. Lipella Pharmaceuticals has announced promising results from its ...

Please provide your email address to receive an email when new articles are posted on . The standardized overall prevalence rate of lichen planus was 0.15%. Among those treated with systemic ...

Background: Photodynamic therapy (PDT) is a new option for oral lichen planus (OLP) management; however, there are different opinions on the efficacy of PDT for OLP. The aim of this study was to ...

PITTSBURGH, PA, April 22, 2025 (EZ Newswire) -- Lipella Pharmaceuticals (Nasdaq: LIPO), a clinical-stage biotechnology company focused on reformulating existing therapeutics for underserved conditions ...

Oral lichen planus (OLP) is a chronic, immune‐mediated mucosal disorder characterised by a range of clinical presentations, from asymptomatic reticular patterns to painful erosive lesions. The ...

AMSTERDAM — Treatment with ruxolitinib cream, 1.5%, achieved rapid and marked reductions in the clinical signs and symptoms of cutaneous lichen planus, including itch and skin pain, both when given ...